v3.25.4
Consolidated Statements of Equity (Deficit) - USD ($)
shares in Millions, $ in Millions
Total
Common stock
Treasury Stock, Common
Additional paid-in capital
Retained earnings (accumulated deficit)
Accumulated other comprehensive loss
Noncontrolling interest
Beginning balance at Dec. 31, 2022 $ 17,287 $ 18 $ (4,594) $ 19,245 $ 4,784 $ (2,199) $ 33
Beginning balance (in shares) at Dec. 31, 2022   1,769          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,863 $ 0 0 0 4,863 0 0
Other comprehensive loss, net of tax (106) 0 0 0 0 (106) 0
Dividends declared (10,647) 0 0 0 (10,647) 0 0
Purchases of treasury stock (1,978) $ 0 (1,978) 0 0 0 0
Purchases of treasury stock (in shares)   (12)          
Stock-based compensation plans and other 974 $ 0 39 935 0 0 0
Stock-based compensation plans and other (in shares)   9          
Change in noncontrolling interest 4 $ 0 0 0 0 0 4
Ending balance at Dec. 31, 2023 10,397 $ 18 (6,533) 20,180 (1,000) (2,305) 37
Ending balance (in shares) at Dec. 31, 2023   1,766          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,278 $ 0 0 0 4,278 0 0
Other comprehensive loss, net of tax 380 0 0 0 0 380 0
Dividends declared (11,178) 0 0 0 (11,178) 0 0
Purchases of treasury stock (1,703) $ 0 (1,703) 0 0 0 0
Purchases of treasury stock (in shares)   (9)          
Stock-based compensation plans and other 1,188 $ 0 35 1,153 0 0 0
Stock-based compensation plans and other (in shares)   8          
Change in noncontrolling interest 2 $ 0 0 0 0 0 2
Ending balance at Dec. 31, 2024 3,364 $ 18 (8,201) 21,333 (7,900) (1,925) 39
Ending balance (in shares) at Dec. 31, 2024   1,765          
Increase (Decrease) in Stockholders' Equity              
Net earnings attributable to AbbVie Inc. 4,226 $ 0 0 0 4,226 0 0
Other comprehensive loss, net of tax 781 0 0 0 0 781 0
Dividends declared (11,819) 0 0 0 (11,819) 0 0
Purchases of treasury stock (980) $ 0 (980) 0 0 0 0
Purchases of treasury stock (in shares)   (5)          
Stock-based compensation plans and other 1,197 $ 0 35 1,162 0 0 0
Stock-based compensation plans and other (in shares)   8          
Change in noncontrolling interest 3 $ 0 0 0 0 0 3
Ending balance at Dec. 31, 2025 $ (3,228) $ 18 $ (9,146) $ 22,495 $ (15,493) $ (1,144) $ 42
Ending balance (in shares) at Dec. 31, 2025   1,768